ClinicalTrials.gg
Not yet recruitingNCT07552181Updated Aug 5, 2026

Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer

A Phase 2 interventional study of Live biotherapeutic product: MO-03 1 capsule PO BID in TNBC - Triple-Negative Breast Cancer, TNBC and Early Stage Triple-Negative Breast Carcinoma, sponsored by Yuan Yuan. Not yet recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Yuan Yuan · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 645 studies in Triple Negative Breast Neoplasms with a site in United States — 159 open to participants now, 263 under way, 16 of them phase 3. Triple Negative Breast Neoplasms · United States.

Planned enrollment
312th of 605
50 · median 52
Started
2026
with 37 others
Phase 2
191 of 645
45 open now
Primary completion
2035-09
later than 262 of 262 live
Registered
628th of 645
by date

Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, this one is the 312th largest by planned enrollment of the 605 interventional ones that give a count, is one of 38 that started in 2026, is one of 191 in phase 2, reaches primary completion later than 262 of the 262 other live ones, and was the 628th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

159 of the 645 studies in Triple Negative Breast Neoplasms with a site in United States are open now. Recruiting first, the newest first:

154 more — sign in →

All 159 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Triple Negative Breast Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a single-arm and single site phase II trial combination of chemotherapy and pembrolizumab with LBP MO-03 in 50 trial participants with early triple negative breast cancer. MO-03 will be given at a dose of 4 x 10e9 CFU per capsule, 1 capsule taken orally twice daily. Patients will receive standard of care pembrolizumab 200 mg every 3 weeks in concurrent with a regimen of chemotherapy. Please refer to Table 2 for a summary of the chemo-immunotherapy with pembrolizumab containing regimens. Patients will continue to take MO-03 up until the day prior to surgery (lumpectomy or mastectomy). Post-surgery, patients will come in for a 2-week follow-up and then enter survival follow-up annually for 5 years.

03

Conditions studied

  • TNBC - Triple-Negative Breast Cancer
  • TNBC
  • Early Stage Triple-Negative Breast Carcinoma

Keywords

  • Pembrolizumab
  • Neoadjuvant Chemo-Immunotherapy
  • TNBC
  • High-risk early stage TNBC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or male age ≥ 18 years of age.
  • Patients with high-risk early stage triple negative breast cancer. Triple negative status will be defined as ER≤10%, PR≤10%, negative (by FISH) per ASCO-CAP guidelines.
  • Clinically staging T1c any N M0 or any T N1-3 M0.
  • Willing to provide FFPE from baseline standard of care and post-treatment residual tumor at the time of surgery.
  • 0-1
  • Patients must have adequate organ function as defined in the following. Specimens must be collected within 28 days prior to the start of study treatment.
  • For patients who will receive regimen 1 only: Participants must have adequate cardiac function. Participants must have ≥ 50% as assessed by either ECHO or MUGA within 28 days prior to the start of treatment. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents must have a clinical risk assessment of cardiac function using the Functional Classification and must be class 2B or better.
  • Women of (WOCBP) must have a negative urine or serum pregnancy test within 28 days of the start of treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  • Male participants: A male participant must agree to use a as detailed in Appendix B of this protocol during the treatment period and for at least 120 days after the last dose of MO-03 and refrain from donating sperm during this period.
  • Female participants: A female participant is eligible to participate if she is not pregnant (see Appendix B), not breastfeeding, and at least one of the following conditions applies:

    i. Not a woman of childbearing potential (WOCBP) as defined in Appendix B OR ii. Females of child-bearing potential must be willing to use effective contraception during study and for 120 days after the last dose of MO-03.

  • Written obtained from subject and ability for subject to comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Participants with known (HIV) infection must be on effective anti-retroviral therapy at registration and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration.
  • Participants with evidence of chronic virus (HBV) infection must have undetectable HBV viral load while on suppressive therapy on the most recent test results obtained within 6 months prior to registration, if indicated.

Note: No testing for Hepatitis B is required unless mandated by local health authority.

  • Participant must not have uncontrolled diabetes or hypertension in the opinion of treating investigator.
  • Participant must not have had a major surgery within 14 days prior to screening.
  • Participant must not have severe infection within 14 days prior to enrollment.
  • Prohibited Treatments and/or Therapies:

    • Any prior chemotherapy, biological therapy, immunotherapy for the current breast cancer diagnosis prior to start of study intervention
    • Prior use of is prohibited
    • Prior breast surgery or radiation therapy for current invasive breast cancer
    • Participants must not have a diagnosis of immunodeficiency and be receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to enrollment.
    • Participants must not have active disease that has required systemic treatment in 2 years prior to enrollment (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroidreplacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
    • Participants must not have a history of (non-infectious) pneumonitis that required steroids or has current (non-infectious) pneumonitis.
    • Any within 30 days prior to the first dose of study drug and for 3 months after chemo-immunotherapy. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
    • Participants on any dose of warfarin. Use of low molecular weight heparin, antithrombin agents, anti- agents or factor Xa inhibitors is allowed
    • Participants may not use any other live biotherapeutic products (LBP) or supplementary use of probiotics in pill form during their participation in the study (e.g., Ferring's Rebyota, Vowst)
  • Participants may not be currently participating in or participated in a study of an agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.
  • Known allergy to any of the components within the study agents and/or their (i.e., corn starch, lactose, microcrystalline cellulose, croscarmellose sodium or magnesium stearate).
  • Medical history and concurrent diseases:

    • Any prior except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for at least five years
    • Known active and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (Note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention
    • History of (non-infectious) pneumonitis that required steroids or has current pneumonitis
    • Known history of active TB (Mycobacterium tuberculosis)
  • Intercurrent or historic medical condition that increases subject risk in the opinion of the Investigator. Eligibility may be revisited for intercurrent medical conditions once resolution/recovery is deemed adequate by the investigator (e.g., recovery from major surgery, completion of treatment for severe infection).
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Has had an allogenic tissue/solid organ transplant.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Single Arm

    Live biotherapeutic product

    Drug: Live biotherapeutic product: MO-03 1 capsule PO BID

Interventions

  • DrugLive biotherapeutic product: MO-03 1 capsule PO BID

    Live biotherapeutic product: MO-03 1 capsule PO BID + standard of care pembrolizumab and carbo-docetaxel or carbo-paclitaxel followed by Adriamycin cyclophosphamide

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response (pCR)

    Pathological complete response (pCR) will be defined as the absence of invasive residual disease in the breast and lymph nodes. This will be assessed at the time of surgery. Pathological complete response will be evaluated using residual cancer burden (RCB) classifier defined by ASCO/CAP guidelines.

    Time frame: Time of Surgery

Secondary outcomes

  1. Event Free Survival (EFS)

    Event free survival is measured from the time of surgery to the first occurrence of any of the following events: disease progression or recurrence (local, regional, or distant), or death from any cause. During 5 year follow up.

    Time frame: Up to 5 years after surgery

  2. Invasive Disease-Free Survival (IDFS)

    Invasive disease-free survival is measured from the time of surgery until recurrence of invasive breast cancer (local, regional, or distant), death from any cause, or up to 5 years after treatment, whichever occurs first

    Time frame: Up to 5 years after treatment

  3. Overall Survival (OS)

    Overall survival is defined as the rate of patients who remain alive at the end of follow-up.

    Time frame: Up to 5 years after treatment

  4. Patient Quality of Life

    Change in patient's quality of life scores by PROMIS (Patient-Reported Outcomes Measurement Information System) Fatigue from baseline to the 6-month post-operative follow-up visit.

    Time frame: 6 month

  5. Patient Quality of Life

    Change in patient's quality of life scores by PROMIS-29 (Patient-Reported Outcomes Measurement Information System) from baseline to the 6-month post-operative follow-up visit.

    Time frame: 6 month

  6. Patient Quality of Life

    Change in patient's quality of life scores by EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30) from baseline to the 6-month post-operative follow-up visit.

    Time frame: 6 month

  7. Safety and Toxicity of MO-03

    Safety and toxicity will be assessed by the number of adverse events at least possibly related to MO-03 per NCI's CTCAE v5.0 from baseline until the post-operative/EOT visit.

    Time frame: From Baseline till end of treatment

07

Study locations

3 sites
  • Cedars-Sinai Medical Center Beverly Hills
    Beverly Hills, California 90211, United States
    • Clinical Trial Recruitment Navigator · ContactGroupCancerTrialInformation@cshs.org · 310-423-5842
    • Yuan Yuan, MD · Principal investigator
    • Philomena McAndrew, MD · Sub investigator
    • Karissa Britten, MD · Sub investigator
    • Maryliza El-Masry, MD · Sub investigator
  • CS Cancer at Valley Oncology Medical Group
    Tarzana, California 91356, United States
    • Ryan Ponec, MD · Sub investigator
    • Natasha Banerjee, MD · Sub investigator
    • Mazen Jizzini, MD · Sub investigator
  • Hunt Cancer Institute, an Affiliate of CS Cancer
    Torrance, California 90505, United States
    • Sarah Valdez · Contactsarah.valdez@tmphysicians.com · 3107503300
    • David Chan, MD · Sub investigator
    • Vanessa Dickey, MD · Sub investigator
    • Hugo Hool, MD · Sub investigator
    • Swati Skiaria, MD · Sub investigator
    • Syed Jilani, MD · Sub investigator
    • Andrew Horodner, MD · Sub investigator
    • Thomas Lowe, MD · Sub investigator
    • Justin Tiulim, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2035, 108 months later.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 108 months is above that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
Apr 27, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2035
CompletionEst.
Sep 2035
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07552181
Lead sponsor
Yuan Yuan
Collaborators
Osel, Inc., Miyarisan Pharmaceuticals, Co., Ltd.
Responsible party
Yuan Yuan (Sponsor-Investigator, Cedars-Sinai Medical Center) — Sponsor-investigator
First posted
Apr 27, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2035 (estimated)
Completion
Sep 2035 (estimated)
Last update
Aug 5, 2026

Study contacts

Clinical Trials Navigator
Contact
GroupCancerTrialInformation@cshs.org
310-423-5842
Yuan Yuan, MD
Contact
yuan.yuan@csmc.edu
Yuan Yuan, MD
principal investigator · Cedars-Sinai Medical Center
Jin Sun Lee-Bitar, MD
principal investigator · Cedars-Sinai Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion